Clinical Trial Search

Primary: Durability of Response (Maintenance of an ACR20 Response or Greater), Which Was Measured at Each Visit in Subjects of RA — 117 Participants

Primary: Percentage of Participants With Complete Clearance of Actinic Keratosis (AK) — 31.3; 1.0 percentage of participants — p=<0.001

Primary: Expansion Part: Annualized Bleeding Rate (ABR) for Treated Bleeds — 2.4 treated bleed rate per year

Primary: Percentage of Participants With Complete Clearance of Actinic Keratosis (AK) — 25.8; 0.0 percentage of participants — p=<0.001

Primary: Percentage of Participants With Complete Clearance of Actinic Keratosis (AK) — 22.0; 3.0 percentage of participants — p=<0.001

Primary: Quantitative Myasthenia Gravis (QMG) Score — 7.8; 8.5; 7.9; 15.0 scores on a scale — p=0.0004

Primary: Gestational Sac Expulsion With One Treatment Dose on Day 3 (Visit 2) and no Need for Additional Medical or Surgical Intervention Within 30 Days of Treatment. — 100; 124…

Primary: Number of Participants With An Improvement in Vision, as Measured by an Increase of 15 Letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) Vision Chart…

Primary: Percent of Participants With Loss of Psoriasis Area and Severity Index (PASI) 75 Response up to Week 68 — 49.8; 25.4; 74.3; 64.7 Cummulative rate — p=<0.0001

Primary: Efficacy Was Not Measured in This Study. The Number of Deaths in the Long Term Follow-up Will be Reported. — 0 Participants

Primary: Number of Participants With Complete Response (Success of Initial PONV Treatment) — 80; 96; 67 Participants — p=0.003

Primary: Complete Response (Success of Initial PONV Treatment) — 60; 59; 39 Participants — p=0.016

Primary: Overall Survival — 15.3; 17.1 months — p=0.12085

Primary: Event-free Survival (EFS) — 0.36; 0.41; 0.37 Proportion of participants — p=0.84

Primary: Study Period 1: Change in DAS28-CRP Score From Baseline at Week 12 in Patients Treated With GP2017 and Patients Treated With Humira — -2.16; -2.18 scores on a scale